The results revealed that in breast cancer PDOs, HER-2 and estrogen receptor (ER) exhibited strong immunoreactivity, whereas progesterone receptor (PR) expression was lower, consistent with the phenotype of primary breast cancer (Figure 2a). This evidence concerns the gene PGR and breast carcinoma.